you But what and few of joining Thank happened, few strategy. R&D minutes, thank are explain is me to minutes call, take we to so will a previously let call. next going. our provide understand we you, everyone is a review easier Aileron's inaugural it since In where and the that earnings has for Rick, this operations today's
subsequently of When make significant in-depth changes of was I to our took action to on assessment strategy. We refocused prompt and Aileron R&D the complete of things to we a role corporate took year one an first ago, CEO the did the strategy company. our
took Officer, Annis company later our as Officer, of they're the team the while to over of Dr. the onto we team Chief such depths all This of I me the executive Medical appointed and Chief Kathryn brought Finance. the call knew and and Gregory this today. Rick more I Research is and group as with at on executive we team we strength to Head Business Wanstall to that add time Allen wanted Vukovic Head elevated as as
inhibitor will R&D XXXX our this that two to a we which strategy clinical new created we MDMX/MDMX is call. programs on for as ALRN-XXXX, refer asset dual lead a Jointly, focused during first-in-class
we Our first program cancers. IBRANCE, is with Pfizer's program palbociclib, MDMX-amplified our or against combine XXXX where
against is XXXX Phase patients all MDMX that published There less that had than mutant it shown in X myelopreservation and pXX with were Phase bone agent testing and program, XXXX Previously trials. toxicities other is cancers. substantially X as inhibitors chemotherapeutic cells marrow in a other our data second was their toxic to us MDMX inhibitors different
XXXX other have XXXX This of created palbociclib collaboration the the inhibitor with test to and MDMX in MDMX-amplified that Pfizer's bone in anti-cancer marrow and drugs this opportunity facilitated between combination toxicities to a our combine development us Pfizer cancers. clinical
initiated and pleased we in present from year, of Phase interim were which this included a results trial this evaluate year positive this with we Xa from cohort Earlier to XXXX palbociclib XX ESMO patients. combination expansion at to September data in
half about on of with advanced In analysis, subgroup, patients efficacy virtually this all our with patient we patients XX liposarcoma had received with associated previously prior a and poor having of all more half them a about of or prognosis. been liposarcoma, subtype with them metastatic of having assessments our MDMX-amplified these interim two Nearly dedifferentiated therapy. largest focused liposarcoma, diagnosed lines treated had disease
us considering patients This reported three for the for these X.X by is liposarcoma. result was for we medical a progression-free in fact the line chemotherapies second and less this survival or evidenced our median currently progression-free for need approved months is only and which patients the of high unmet very survival encouraging that analysis, third liposarcoma months median In our for interim a showed patients.
as only a XX% our alone for a less and observed not any than of previously of for rate did are patients. progression-free therapy, at rate shown of we achieve pretreated we responses a have progression-free palbociclib result XX survival substantially which proud survival XX% weeks has were partial we palbociclib Although, published those patients complete our because or data combination monotherapy
have our We've accelerate evaluate and among cohort combination in therapy data clinical helped on investigators in for this order Xa we XX increased this quarter the in cancers. of in announce rate to Phase enrollment second enrollment and to And final fuel other expanded results MDMX-amplified These patients to interest even trial. XXXX. trial this the this be to to of continue from enrollment with track the
related mutant myelopreservation our turn sometimes a in as development Chemotherapies to let's toxicities pXX against fatal patients cause of chemotherapy toxicities with thrombocytopenia. is and such can XXXX neutropenia agent cancers. Now, second clinical study and program. The severe
currently and the cancer. chemotherapeutic when chemotherapeutic inadequate An lung or drug toxicities is better of small manage biotech cell with management and advancement challenge. chemotherapeutic in prevent called to was patients a ways toxicities bone their huge in made finding another company has GX toxicity cell normal candidate important been recently paused that Therapeutics cells marrow announced cycle healthy reduced thereby arrest Unfortunately
indication events Since program for us on a important regulatory to informs our in of were set cornerstone strong then a the has reported the meetings factors for based because program non-clinical the excellent our our clinical with arrest cycle of myelopreservation. that trials of XXXX GX All myelopreservation our shows also commence regulatory properties. us myelopreservation supports that using with cell pathway data these in data creation and Therapeutics non-clinical has encouraged authorities. These and
in a a marrow a pXX mutant advanced trial vivo lung in side can to evaluating clinic an XXXX believe Phase of October And neurological into in the human at bone clinical have agent to marrow findings by showed translate as on toxicities our as improvement cell Xb/X limit mouse cells presented cells rest that we XX EORTC We as patients our program chemotherapy. reversible of myelopreservating effects chemotherapy. small result, cancers. with in we conference low As vivo this year, that caused doses Triple and in triggered XXXX ex cycle the bone cell
trial trial trials to myelopreservation and portion XX Phase The enroll will this patients cancers. select recommended use ongoing will patients of existing designed future to for Phase is pXX gene with identify standard tests and to up XXXX. mutant a dose X Xb This
We're of possibility biomarker-based drug optimize this very excited patients medicine taking. our sets XXXX GX precision our selection the effects approach. from of approach And applying by to Therapeutics about the that a apart the
on data myelopreservation our without additional Based decided recently reallocate two cash from to our program shortening our runway. for to early drug compelling cohorts adding non-clinical discovery plans we our program, capital
optimization XX and alternating treat with more would Phase ongoing chemotherapy concept. recommended proof XXXX cycles plus chemotherapy use expansion alone Xb patients approximately We new added cohort and randomized a definitive cancer. X an Phase with This trial patients intent in to create small the from cohort our of dose lung of cell the with with dose
we an breadth of to cohort approach of designed adding the XXXX is myelopreservation evaluate patients taking Secondly, as XX with approximately non-small expansion cohort a agent. the new with lung cell This are cancer.
Our X current Phase plan additional And identified availability, mid-XXXX. second is the trial into enrolling to start a we into resource in portion of patients contingent on two to patients recommended after start Xb/X in XXXX, of we have these cohorts quarter the Phase Phase expect enrolling the X dose.
about XXXX. to over are hand the Before of tell we potential how Rick, let you excited I me
also efficiently Given in six months anticipate programs, agent as from two optimization just several forward therapy second in XXXX to palbociclib the committed myelopreservation of and combination for seven we as possible. expeditiously the well ongoing have data as with the from dose to milestones shared final quarter results date, fully the next we're clinical to development the XXXX XXXX. We as our including presentation data bringing in second of our as quarter XXXX the
With our of financials the provide Rick turn now floor for strategy, overview yours. of our call this operations over the I'll quarter. overview to an is R&D and to the Rick,
